Fennec Pharmaceuticals Announces Closing of Offering of Common Shares — Neutral

FENC   GlobeNewsWire — November 17, 2025

RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its underwritten registered public offering of 5,366,667 common shares (which amount includes exercise in full of the underwriters' option to purchase additional common shares) at a public offering price of $7.50 per share. Fennec's total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) are approximately $40,250,000.

image for news Fennec Pharmaceuticals Announces Closing of Offering of Common Shares

NEWCASTLE & HOUSTON--(BUSINESS WIRE)--TechnipFMC (NYSE: FTI) has been awarded a substantial(1) integrated Engineering, Procurement, Construction, and Installation (iEPCITM) contract by Eni SpA (ENI.MI) for the deepwater Maha project offshore Indonesia. The project represents Eni's first deployment of TechnipFMC's Subsea 2.0® configure-to-order (CTO) technology in Indonesia. The award leverages experience gained through a series of successful projects with Eni in the region, including Jangkrik a.

image for news TechnipFMC Awarded Substantial iEPCI™ Contract for Eni's Maha Project in Indonesia

LAS VEGAS--(BUSINESS WIRE)--Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) today announced that it has released an investor presentation in connection with its 2025 Annual Meeting of Shareholders (the “Annual Meeting”) to be held on December 12, 2025. All Cannae shareholders of record as of the close of business on October 30, 2025, will be entitled to vote at the Annual Meeting. The presentation can be found at www.cannaeholdings.com. Over the past 21 months, Cannae has shifted.

image for news Cannae Holdings, Inc. Releases Investor Presentation Highlighting Superior Board Nominees and Path to Unlock Further Long-Term Value

Gary Haase to Join Everest as EVP, CEO of Legacy Operations — Neutral

EG   Business Wire — November 17, 2025

HAMILTON, Bermuda--(BUSINESS WIRE)--Everest Group, Ltd. (NYSE: EG), a global underwriting leader providing world-class reinsurance and specialty insurance solutions, today announced the appointment of Gary Haase as Executive Vice President and CEO of Legacy Operations, effective December 1, 2025. He will report to Jim Williamson, Everest's President and CEO, and will join the Company's Executive Leadership Team. The appointment follows Everest's recent $2B renewal rights sale of its commercial.

image for news Gary Haase to Join Everest as EVP, CEO of Legacy Operations

Helios Technologies Promotes Jeremy Evans to Chief Financial Officer — Neutral

HLIO   Business Wire — November 17, 2025

SARASOTA, Fla.--(BUSINESS WIRE)--Helios Technologies, Inc. (NYSE: HLIO) Promotes Jeremy Evans to Chief Financial Officer.

image for news Helios Technologies Promotes Jeremy Evans to Chief Financial Officer

Dell, HPE stocks sank after Morgan Stanley downgraded several computer hardware companies. The bank said that the current pricing "supercycle" poses a significant risk to computer manufacturers' earnings.

image for news Dell, HPE shares sink after Morgan Stanley downgrades — computer hardware stocks also hit

Oracle risk/reward profile ‘favorable' following stock pullback — Positive

ORCL   Proactive Investors — November 17, 2025

Analysts at Jefferies have highlighted Oracle Corp (NYSE:ORCL, XETRA:ORC)'s favorable risk/reward profile following a recent 32% decline in the company's shares from their September peak. The analysts have a ‘Buy' rating on Oracle and $400 price target, implying upside of 79% from Oracle's share price at their time of writing.

image for news Oracle risk/reward profile ‘favorable' following stock pullback

TPG RE Finance Trust, Inc. Closes $1.1 Billion Commercial Real Estate CLO — Neutral

TRTX   Business Wire — November 17, 2025

NEW YORK--(BUSINESS WIRE)--TPG RE Finance Trust, Inc. (NYSE: TRTX) (“TRTX” or the “Company”) announced today that it closed TRTX 2025-FL7, a $1.1 billion managed Commercial Real Estate Collateralized Loan Obligation (“CRE CLO”). The Company placed approximately $957.0 million of investment grade securities with institutional investors providing term financing on a non-mark-to-market, non-recourse basis. TRTX 2025-FL7 includes a 30-month reinvestment period, an advance rate of 87.0%, and a weigh.

image for news TPG RE Finance Trust, Inc. Closes $1.1 Billion Commercial Real Estate CLO

XP Inc. Reports Third Quarter 2025 Results — Neutral

XP   Business Wire — November 17, 2025

SÃO PAULO--(BUSINESS WIRE)--XP Inc. (NASDAQ: XP) (“XP” or the “Company”), a leading tech-enabled platform and a trusted pioneer in providing low-fee financial products and services in Brazil, reported today its financial results for the third quarter of 2025. Summary Operating KPIs Operating Metrics (unaudited) 3Q25 3Q24 YoY 2Q25 QoQ Total Client Assets (in R$ bn) 1,425 1,270 12% 1,372 4% Total Net Inflow (in R$ bn) 29 34 -14% 10 204% Annualized Retail Take Rate 1.24% 1.33% -9 bps 1.25% -1 bps.

image for news XP Inc. Reports Third Quarter 2025 Results

Starboard Value purchased 7,024,848 shares in Bill Holdings, increasing reported holdings by $372.11 million. The transaction represents 7% of Starboard Value's 13F reportable assets under management.

image for news Starboard Value Takes a Hefty 8% Stake in Bill Holdings: Should Investors Buy Too?

WaterBridge Infrastructure LLC (WBI) Q3 2025 Earnings Call Transcript — Neutral

WBI   Seeking Alpha — November 17, 2025

WaterBridge Infrastructure LLC ( WBI ) Q3 2025 Earnings Call November 13, 2025 11:30 AM EST Company Participants Mae Herrington - Director of Investor Relations Jason Long - CEO & Director Michael Reitz - COO & President Scott McNeely - Executive VP & CFO Conference Call Participants Theresa Chen - Barclays Bank PLC, Research Division Elias Jossen - JPMorgan Chase & Co, Research Division Derrick Whitfield - Texas Capital Securities, Research Division Kevin MacCurdy - Pickering Energy Partners LP Praneeth Satish - Wells Fargo Securities, LLC, Research Division Presentation Operator Hello, and thank you for standing by. My name is …

image for news WaterBridge Infrastructure LLC (WBI) Q3 2025 Earnings Call Transcript

Hong Kong, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Click Holdings Limited (“Click Holdings” or “Click” or “we” or “us”, NASDAQ: CLIK) and its subsidiaries (collectively, the “Company”), Hong Kong's only Nasdaq-listed leader in human resources and senior care solutions, announced to acquire 100% equity interest in Bowser Human Resources Limited (“Bowser”) and Top Team Consultants Limited (“Top Team”), being two Hong Kong-based human resources solutions providers operating in the region, by the issuance of 1,885,350 and 232,256 Class A ordinary shares of the Company respectively. These acquisitions will supercharge Click's strategic growth, unlock synergies, and propel the Company to new …

image for news Click Holdings Limited (CLIK) Announces Strategic Acquisitions of HK-based HR Specialists to Ignite Synergies and Accelerate Market Leadership in Human Resources Solutions

3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List — Positive

INCY  PFE  PPH  VRTX  XBI  XLV   Seeking Alpha — November 17, 2025

The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in the Russell 1000 universe with positive recent consensus revisions to 2026 EPS estimates and that trade at attractive valuations. Goldman sees "more opportunity for alpha than beta" as wide return dispersion and increasing M&A activity in healthcare may favor selected winners.

image for news 3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — Neutral

TELA   GlobeNewsWire — November 17, 2025

MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of (i) restricted stock units covering 30,200 shares of its common stock to seventeen newly-hired employees and (ii) an option to purchase 25,000 shares of its common stock to one employee, with a grant date of November 10, 2025 (the "Grant Date"). The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception …

image for news TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Largest real-world analysis of AI-driven breast cancer screening in US demonstrates increased cancer detection rate, consistency across patient populations

image for news Landmark Nature Health Study Demonstrates the Effectiveness of DeepHealth's Novel AI-Powered Breast Cancer Detection Workflow

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 — Neutral

CADL   GlobeNewsWire — November 17, 2025

NEEDHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced it will host a virtual Research and Development (R&D) Event from 11:00 am – 1:45 pm ET on Friday, December 5, 2025.

image for news Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), advanced breast cancer (“ABC”). The NDA was submitted under the FDA's Real-Time Oncology Review (“RTOR”) program, which is intended to facilitate shorter regulatory review periods. Gedatolisib previously received both Breakthrough Therapy and Fast Track designations based on promising preliminary clinical data. The …

image for news Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

The Andersons to Present at Stephens Annual Investment Conference — Neutral

ANDE   PRNewsWire — November 17, 2025

MAUMEE, Ohio , Nov. 17, 2025 /PRNewswire/ -- The Andersons, Inc. (Nasdaq: ANDE) announces that it will present at the Stephens Annual Investment Conference on Wednesday, November 19, 2025. President and Chief Executive Officer Bill Krueger and Executive Vice President and Chief Financial Officer Brian Valentine will speak at the conference at 3 p.m.

image for news The Andersons to Present at Stephens Annual Investment Conference

RADIANT LOGISTICS ANNOUNCES RENEWAL OF ITS STOCK REPURCHASE PROGRAM — Neutral

RLGT   PRNewsWire — November 17, 2025

RENTON, Wash. , Nov. 17, 2025 /PRNewswire/ -- Radiant Logistics, Inc. (NYSE American: RLGT), a technology-enabled global transportation and value-added logistics services company, today announced that its board of directors has authorized the repurchase of up to five million shares of the Company's common stock through December 31, 2027.

image for news RADIANT LOGISTICS ANNOUNCES RENEWAL OF ITS STOCK REPURCHASE PROGRAM

Transaction Highlights Raised $975.0 million gross proceeds through a new offering of convertible senior notes due in November 2031 Has agreed to repurchase approximately $755.7 million principal amount of existing 1.25% convertible notes due in 2026 NEWARK, Calif. , Nov. 17, 2025 /PRNewswire/ -- Lucid Group, Inc. (Nasdaq: LCID), maker of the world's most advanced electric vehicles, today announced the closing of $975.0 million aggregate principal amount of convertible senior notes due 2031, including the exercise in full of the option granted to the initial purchasers to purchase up to $100.0 million aggregate principal amount of notes.

image for news Lucid Group, Inc. Announces Closing of Private Offering of $975.0 Million of Convertible Senior Notes Due 2031